Activin signaling as an emerging target for therapeutic interventions

Tsuchida K, Nakatani M, Uezumi A, Murakami T, Cui X: Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer. Endocr J. 2008, 55: 11-21. 10.1507/endocrj.KR-110. Massagué J, Gomis RR: The logic of TGFbeta signaling. FEBS Lett. 2006, 580: 2811-2820. 10.1016/j.febslet.2006.04.033. Anderson SB, Goldberg AL, Whitman M: Identification of a novel pool of extracellular pro-myostatin in skeletal muscle. J Biol Chem. 2008, 283: 7027-7035. 10.1074/jbc.M706678200. Harrison CA, Gray PC, Vale WW, Robertson DM: Antagonists of activin signaling: mechanisms and potential biological applications. Trends Endocrinol Metab. 2005, 16: 73-78. 10.1016/j.tem.2005.01.003. Lee SJ: Regulation of muscle mass by myostatin. Annu Rev Cell Dev Biol. 2004, 20: 61-86. 10.1146/annurev.cellbio.20.012103.135836. Wu HH, Ivkovic S, Murray RC, Jaramillo S, Lyons KM, Johnson JE, Calof AL: Autoregulation of neurogenesis by GDF11. Neuron. 2003, 37: 197-207. 10.1016/S0896-6273(02)01172-8. Oxburgh L, Chu GC, Michael SK, Robertson EJ: TGFbeta superfamily signals are required for morphogenesis of the kidney mesenchyme progenitor population. Development. 2004, 131: 4593-4605. 10.1242/dev.01324. Dichmann DS, Yassin H, Serup P: Analysis of pancreatic endocrine development in GDF11-deficient mice. Dev Dyn. 2006, 235: 3016-3025. 10.1002/dvdy.20953. Shen MM: Nodal signaling: developmental roles and regulation. Development. 2007, 134: 1023-1034. 10.1242/dev.000166. Mathews LS, Vale WW: Expression cloning of an activin receptor, a predicted transmembrane serine kinase. Cell. 1991, 65: 973-982. 10.1016/0092-8674(91)90549-E. Feng XH, Derynck R: Specificity and versatility in tgf-beta signaling through Smads. Annu Rev Cell Dev Biol. 2005, 21: 659-693. 10.1146/annurev.cellbio.21.022404.142018. Gray PC, Harrison CA, Vale W: Cripto forms a complex with activin and type II activin receptors and can block activin signaling. Proc Natl Acad Sci USA. 2003, 100: 5193-5198. 10.1073/pnas.0531290100. Onichtchouk D, Chen YG, Dosch R, Gawantka V, Delius H, Massagué J, Niehrs C: Silencing of TGF-beta signalling by the pseudoreceptor BAMBI. Nature. 1999, 401: 480-485. 10.1038/46794. Sekiya T, Adachi S, Kohu K, Yamada T, Higuchi O, Furukawa Y, Nakamura Y, Nakamura T, Tashiro K, Kuhara S, et al.: Identification of BMP and activin membrane-bound inhibitor (BAMBI), an inhibitor of transforming growth factor-beta signaling, as a target of the beta-catenin pathway in colorectal tumor cells. J Biol Chem. 2004, 279: 6840-6846. 10.1074/jbc.M310876200. Tsukazaki T, Chiang TA, Davison AF, Attisano L, Wrana JL: SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor. Cell. 1998, 95: 779-791. 10.1016/S0092-8674(00)81701-8. Wu G, Chen YG, Ozdamar B, Gyuricza CA, Chong PA, Wrana JL, Massague J, Shi Y: Structural basis of Smad2 recognition by the Smad anchor for receptor activation. Science. 2000, 287: 92-97. 10.1126/science.287.5450.92. Shoji H, Tsuchida K, Kishi H, Yamakawa N, Matsuzaki T, Liu Z, Nakamura T, Sugino H: Identification and characterization of a PDZ protein that interacts with activin type II receptors. J Biol Chem. 2000, 275: 5485-5492. 10.1074/jbc.275.8.5485. Iida J, Ishizaki H, Okamoto-Tanaka M, Kawata A, Sumita K, Ohgake S, Sato Y, Yorifuji H, Nukina N, Ohashi K, et al.: Synaptic scaffolding molecule alpha is a scaffold to mediate N-methyl-D-aspartate receptor-dependent RhoA activation in dendrites. Mol Cell Biol. 2007, 27: 4388-4405. 10.1128/MCB.01901-06. Kurisaki A, Inoue I, Kurisaki K, Yamakawa N, Tsuchida K, Sugino H: Activin induces long-lasting N-methyl-D-aspartate receptor activation via scaffolding PDZ protein activin receptor interacting protein 1. Neuroscience. 2008, 151: 1225-1235. 10.1016/j.neuroscience.2007.12.012. Matsuzaki T, Hanai S, Kishi H, Liu Z, Bao Y, Kikuchi A, Tsuchida K, Sugino H: Regulation of endocytosis of activin type II receptors by a novel PDZ protein through Ral/Ral-binding protein 1-dependent pathway. J Biol Chem. 2002, 277: 19008-19018. 10.1074/jbc.M112472200. Liu ZH, Tsuchida K, Matsuzaki T, Bao YL, Kurisaki A, Sugino H: Characterization of isoforms of activin receptor-interacting protein 2 that augment activin signaling. J Endocrinol. 2006, 189: 409-421. 10.1677/joe.1.06420. Yamakawa N, Tsuchida K, Sugino H: The rasGAP-binding protein, Dok-1, mediates activin signaling via serine/threonine kinase receptors. Embo J. 2002, 21: 1684-1694. 10.1093/emboj/21.7.1684. Inoue Y, Imamura T: Regulation of TGF-beta family signaling by E3 ubiquitin ligases. Cancer Sci. 2008, 99: 2107-2112. 10.1111/j.1349-7006.2008.00925.x. Kang JS, Saunier EF, Akhurst RJ, Derynck R: The type I TGF-beta receptor is covalently modified and regulated by sumoylation. Nat Cell Biol. 2008, 10: 654-664. 10.1038/ncb1728. Lin X, Duan X, Liang YY, Su Y, Wrighton KH, Long J, Hu M, Davis CM, Wang J, Brunicardi FC, et al.: PPM1A functions as a Smad phosphatase to terminate TGFbeta signaling. Cell. 2006, 125: 915-928. 10.1016/j.cell.2006.03.044. Nakano A, Koinuma D, Miyazawa K, Uchida T, Saitoh M, Kawabata M, Hanai J, Akiyama H, Abe M, Miyazono K, et al.: Pin1 Down-regulates Transforming Growth Factor-{beta} (TGF-{beta}) Signaling by Inducing Degradation of Smad Proteins. J Biol Chem. 2009, 284: 6109-6115. 10.1074/jbc.M804659200. Bao YL, Tsuchida K, Liu B, Kurisaki A, Matsuzaki T, Sugino H: Synergistic activity of activin A and basic fibroblast growth factor on tyrosine hydroxylase expression through Smad3 and ERK1/ERK2 MAPK signaling pathways. J Endocrinol. 2005, 184: 493-504. 10.1677/joe.1.05978. de Guise C, Lacerte A, Rafiei S, Reynaud R, Roy M, Brue T, Lebrun JJ: Activin inhibits the human Pit-1 gene promoter through the p38 kinase pathway in a Smad-independent manner. Endocrinology. 2006, 147: 4351-4362. 10.1210/en.2006-0444. Hirota M, Watanabe K, Hamada S, Sun Y, Strizzi L, Mancino M, Nagaoka T, Gonzales M, Seno M, Bianco C, Salomon DS: Smad2 functions as a co-activator of canonical Wnt/beta-catenin signaling pathway independent of Smad4 through histone acetyltransferase activity of p300. Cell Signal. 2008, 20: 1632-1641. 10.1016/j.cellsig.2008.05.003. Wrighton KH, Lin X, Yu PB, Feng XH: Transforming Growth Factor {beta} Can Stimulate Smad1 Phosphorylation Independently of Bone Morphogenic Protein Receptors. J Biol Chem. 2009, 284: 9755-9763. 10.1074/jbc.M809223200. Murakami M, Kawachi H, Ogawa K, Nishino Y, Funaba M: Receptor expression modulates the specificity of transforming growth factor-beta signaling pathways. Genes Cells. 2009, 14: 469-482. 10.1111/j.1365-2443.2009.01283.x. Liu IM, Schilling SH, Knouse KA, Choy L, Derynck R, Wang XF: TGFbeta-stimulated Smad1/5 phosphorylation requires the ALK5 L45 loop and mediates the pro-migratory TGFbeta switch. Embo J. 2009, 28: 88-98. 10.1038/emboj.2008.266. Nakamura T, Takio K, Eto Y, Shibai H, Titani K, Sugino H: Activin-binding protein from rat ovary is follistatin. Science. 1990, 247: 836-838. 10.1126/science.2106159. Thompson TB, Lerch TF, Cook RW, Woodruff TK, Jardetzky TS: The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding. Dev Cell. 2005, 9: 535-543. 10.1016/j.devcel.2005.09.008. Harrington AE, Morris-Triggs SA, Ruotolo BT, Robinson CV, Ohnuma S, Hyvonen M: Structural basis for the inhibition of activin signalling by follistatin. Embo J. 2006, 25: 1035-1045. 10.1038/sj.emboj.7601000. Stamler R, Keutmann HT, Sidis Y, Kattamuri C, Schneyer A, Thompson TB: The structure of FSTL3.activin A complex. Differential binding of N-terminal domains influences follistatin-type antagonist specificity. J Biol Chem. 2008, 283: 32831-32838. 10.1074/jbc.M801266200. Hill JJ, Davies MV, Pearson AA, Wang JH, Hewick RM, Wolfman NM, Qiu Y: The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum. J Biol Chem. 2002, 277: 40735-40741. 10.1074/jbc.M206379200. Matzuk MM, Lu N, Vogel H, Sellheyer K, Roop DR, Bradley A: Multiple defects and perinatal death in mice deficient in follistatin. Nature. 1995, 374: 360-363. 10.1038/374360a0. Tsuchida K, Arai KY, Kuramoto Y, Yamakawa N, Hasegawa Y, Sugino H: Identification and characterization of a novel follistatin-like protein as a binding protein for the TGF-beta family. J Biol Chem. 2000, 275: 40788-40796. 10.1074/jbc.M006114200. Hayette S, Gadoux M, Martel S, Bertrand S, Tigaud I, Magaud JP, Rimokh R: FLRG (follistatin-related gene), a new target of chromosomal rearrangement in malignant blood disorders. Oncogene. 1998, 16: 2949-2954. 10.1038/sj.onc.1201807. Saito S, Sidis Y, Mukherjee A, Xia Y, Schneyer A: Differential biosynthesis and intracellular transport of follistatin isoforms and follistatin-like-3. Endocrinology. 2005, 146: 5052-5062. 10.1210/en.2005-0833. Mukherjee A, Sidis Y, Mahan A, Raher MJ, Xia Y, Rosen ED, Bloch KD, Thomas MK, Schneyer AL: FSTL3 deletion reveals roles for TGF-beta family ligands in glucose and fat homeostasis in adults. Proc Natl Acad Sci USA. 2007, 104: 1348-1353. 10.1073/pnas.0607966104. Frandsen U, Porneki AD, Floridon C, Abdallah BM, Kassem M: Activin B mediated induction of Pdx1 in human embryonic stem cell derived embryoid bodies. Biochem Biophys Res Commun. 2007, 362: 568-574. 10.1016/j.bbrc.2007.07.200. Kim SK, Hebrok M, Li E, Oh SP, Schrewe H, Harmon EB, Lee JS, Melton DA: Activin receptor patterning of foregut organogenesis. Genes Dev. 2000, 14: 1866-1871. Goto Y, Nomura M, Tanaka K, Kondo A, Morinaga H, Okabe T, Yanase T, Nawata H, Takayanagi R, Li E: Genetic interactions between activin type IIB receptor and Smad2 genes in asymmetrical patterning of the thoracic organs and the development of pancreas islets. Dev Dyn. 2007, 236: 2865-2874. 10.1002/dvdy.21303. Kogame M, Matsuo S, Nakatani M, Kurisaki A, Nishitani H, Tsuchida K, Sugino H: ALK7 is a novel marker for adipocyte differentiation. J Med Invest. 2006, 53: 238-245. 10.2152/jmi.53.238. Watanabe R, Shen ZP, Tsuda K, Yamada Y: Insulin gene is a target in activin receptor-like kinase 7 signaling pathway in pancreatic beta-cells. Biochem Biophys Res Commun. 2008, 377: 867-872. 10.1016/j.bbrc.2008.10.074. Tsuchida K, Nakatani M, Yamakawa N, Hashimoto O, Hasegawa Y, Sugino H: Activin isoforms signal through type I receptor serine/threonine kinase ALK7. Mol Cell Endocrinol. 2004, 220: 59-65. 10.1016/j.mce.2004.03.009. Andersson O, Korach-Andre M, Reissmann E, Ibanez CF, Bertolino P: Growth/differentiation factor 3 signals through ALK7 and regulates accumulation of adipose tissue and diet-induced obesity. Proc Natl Acad Sci USA. 2008, 105: 7252-7256. 10.1073/pnas.0800272105. Shen JJ, Huang L, Li L, Jorgez C, Matzuk MM, Brown CW: Deficiency of growth differentiation factor 3 protects against diet-induced obesity by selectively acting on white adipose. Mol Endocrinol. 2009, 23: 113-123. 10.1210/me.2007-0322. Allen DL, Cleary AS, Speaker KJ, Lindsay SF, Uyenishi J, Reed JM, Madden MC, Mehan RS: Myostatin, activin receptor IIb, and follistatin-like-3 gene expression are altered in adipose tissue and skeletal muscle of obese mice. Am J Physiol Endocrinol Metab. 2008, 294: E918-927. 10.1152/ajpendo.00798.2007. Hittel DS, Berggren JR, Shearer J, Boyle K, Houmard JA: Increased secretion and expression of myostatin in skeletal muscle from extremely obese women. Diabetes. 2009, 58: 30-38. 10.2337/db08-0943. McPherron AC, Lawler AM, Lee SJ: Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997, 387: 83-90. 10.1038/387083a0. McPherron AC, Lee SJ: Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci USA. 1997, 94: 12457-12461. 10.1073/pnas.94.23.12457. Clop A, Marcq F, Takeda H, Pirottin D, Tordoir X, Bibe B, Bouix J, Caiment F, Elsen JM, Eychenne F, et al.: A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep. Nat Genet. 2006, 38: 813-818. 10.1038/ng1810. Mosher DS, Quignon P, Bustamante CD, Sutter NB, Mellersh CS, Parker HG, Ostrander EA: A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS Genet. 2007, 3: e79-10.1371/journal.pgen.0030079. Shelton GD, Engvall E: Gross muscle hypertrophy in whippet dogs is caused by a mutation in the myostatin gene. Neuromuscul Disord. 2007, 17: 721-722. 10.1016/j.nmd.2007.06.008. Acosta J, Carpio Y, Borroto I, Gonzalez O, Estrada MP: Myostatin gene silenced by RNAi show a zebrafish giant phenotype. J Biotechnol. 2005, 119: 324-331. 10.1016/j.jbiotec.2005.04.023. Schuelke M, Wagner KR, Stolz LE, Hubner C, Riebel T, Komen W, Braun T, Tobin JF, Lee SJ: Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med. 2004, 350: 2682-2688. 10.1056/NEJMoa040933. Bogdanovich S, Krag TO, Barton ER, Morris LD, Whittemore LA, Ahima RS, Khurana TS: Functional improvement of dystrophic muscle by myostatin blockade. Nature. 2002, 420: 418-421. 10.1038/nature01154. Wagner KR, McPherron AC, Winik N, Lee SJ: Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann Neurol. 2002, 52: 832-836. 10.1002/ana.10385. Bogdanovich S, Perkins KJ, Krag TO, Whittemore LA, Khurana TS: Myostatin propeptide-mediated amelioration of dystrophic pathophysiology. Faseb J. 2005, 19: 543-549. 10.1096/fj.04-2796com. Ohsawa Y, Hagiwara H, Nakatani M, Yasue A, Moriyama K, Murakami T, Tsuchida K, Noji S, Sunada Y: Muscular atrophy of caveolin-3-deficient mice is rescued by myostatin inhibition. J Clin Invest. 2006, 116: 2924-2934. 10.1172/JCI28520. Bartoli M, Poupiot J, Vulin A, Fougerousse F, Arandel L, Daniele N, Roudaut C, Noulet F, Garcia L, Danos O, Richard I: AAV-mediated delivery of a mutated myostatin propeptide ameliorates calpain 3 but not alpha-sarcoglycan deficiency. Gene Ther. 2007, 14 (9): 733-740. 10.1038/sj.gt.3302928. Parsons SA, Millay DP, Sargent MA, McNally EM, Molkentin JD: Age-dependent effect of myostatin blockade on disease severity in a murine model of limb-girdle muscular dystrophy. Am J Pathol. 2006, 168: 1975-1985. 10.2353/ajpath.2006.051316. Nakatani M, Takehara Y, Sugino H, Matsumoto M, Hashimoto O, Hasegawa Y, Murakami T, Uezumi A, Takeda S, Noji S, et al.: Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice. Faseb J. 2008, 22: 477-487. 10.1096/fj.07-8673com. Rodino-Klapac LR, Haidet AM, Kota J, Handy C, Kaspar BK, Mendell JR: Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle Nerve. 2009, 39: 283-296. 10.1002/mus.21244. Li ZB, Kollias HD, Wagner KR: Myostatin directly regulates skeletal muscle fibrosis. J Biol Chem. 2008, 283: 19371-19378. 10.1074/jbc.M802585200. Li ZF, Shelton GD, Engvall E: Elimination of myostatin does not combat muscular dystrophy in dy mice but increases postnatal lethality. Am J Pathol. 2005, 166: 491-497. Lee SJ, Reed LA, Davies MV, Girgenrath S, Goad ME, Tomkinson KN, Wright JF, Barker C, Ehrmantraut G, Holmstrom J, et al.: Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci USA. 2005, 102: 18117-18122. 10.1073/pnas.0505996102. Souza TA, Chen X, Guo Y, Sava P, Zhang J, Hill JJ, Yaworsky PJ, Qiu Y: Proteomic identification and functional validation of activins and bone morphogenetic protein 11 as candidate novel muscle mass regulators. Mol Endocrinol. 2008, 22: 2689-2702. 10.1210/me.2008-0290. Holzbaur EL, Howland DS, Weber N, Wallace K, She Y, Kwak S, Tchistiakova LA, Murphy E, Hinson J, Karim R, et al.: Myostatin inhibition slows muscle atrophy in rodent models of amyotrophic lateral sclerosis. Neurobiol Dis. 2006, 23: 697-707. 10.1016/j.nbd.2006.05.009. Rose FF Jr, Mattis VB, Rindt H, Lorson CL: Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy. Hum Mol Genet. 2009, 18: 997-1005. 10.1093/hmg/ddn426. Mahmoudabady M, Mathieu M, Dewachter L, Hadad I, Ray L, Jespers P, Brimioulle S, Naeije R, McEntee K: Activin-A, transforming growth factor-beta, and myostatin signaling pathway in experimental dilated cardiomyopathy. J Card Fail. 2008, 14: 703-709. 10.1016/j.cardfail.2008.05.003. Cohn RD, Liang HY, Shetty R, Abraham T, Wagner KR: Myostatin does not regulate cardiac hypertrophy or fibrosis. Neuromuscul Disord. 2007, 17: 290-296. 10.1016/j.nmd.2007.01.011. Sugatani T, Alvarez UM, Hruska KA: Activin A stimulates IkappaB-alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors. J Cell Biochem. 2003, 90: 59-67. 10.1002/jcb.10613. Deal C: Potential new drug targets for osteoporosis. Nat Clin Pract Rheumatol. 2009, 5: 20-27. 10.1038/ncprheum0977. Pearsall RS, Canalis E, Cornwall-Brady M, Underwood KW, Haigis B, Ucran J, Kumar R, Pobre E, Grinberg A, Werner ED, et al.: A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. Proc Natl Acad Sci USA. 2008, 105: 7082-7087. 10.1073/pnas.0711263105. Perrien DS, Akel NS, Edwards PK, Carver AA, Bendre MS, Swain FL, Skinner RA, Hogue WR, Nicks KM, Pierson TM, et al.: Inhibin A is an endocrine stimulator of bone mass and strength. Endocrinology. 2007, 148: 1654-1665. 10.1210/en.2006-0848. Yu PB, Deng DY, Lai CS, Hong CC, Cuny GD, Bouxsein ML, Hong DW, McManus PM, Katagiri T, Sachidanandan C, et al.: BMP type I receptor inhibition reduces heterotopic ossification. Nat Med. 2008, 14: 1363-1369. 10.1038/nm.1888. Adkins HB, Bianco C, Schiffer SG, Rayhorn P, Zafari M, Cheung AE, Orozco O, Olson D, De Luca A, Chen LL, et al.: Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo. J Clin Invest. 2003, 112: 575-587. Razanajaona D, Joguet S, Ay AS, Treilleux I, Goddard-Leon S, Bartholin L, Rimokh R: Silencing of FLRG, an antagonist of activin, inhibits human breast tumor cell growth. Cancer Res. 2007, 67: 7223-7229. 10.1158/0008-5472.CAN-07-0805. Hempen PM, Zhang L, Bansal RK, Iacobuzio-Donahue CA, Murphy KM, Maitra A, Vogelstein B, Whitehead RH, Markowitz SD, Willson JK, et al.: Evidence of selection for clones having genetic inactivation of the activin A type II receptor (ACVR2) gene in gastrointestinal cancers. Cancer Res. 2003, 63: 994-999. Su GH, Bansal R, Murphy KM, Montgomery E, Yeo CJ, Hruban RH, Kern SE: ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma. Proc Natl Acad Sci USA. 2001, 98: 3254-3257. 10.1073/pnas.051484398. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE: DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 1996, 271: 350-353. 10.1126/science.271.5247.350. Matzuk MM, Finegold MJ, Mather JP, Krummen L, Lu H, Bradley A: Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice. Proc Natl Acad Sci USA. 1994, 91: 8817-8821. 10.1073/pnas.91.19.8817. Leto G, Incorvaia L, Badalamenti G, Tumminello FM, Gebbia N, Flandina C, Crescimanno M, Rini G: Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin Exp Metastasis. 2006, 23: 117-122. 10.1007/s10585-006-9010-5. Li Q, Kumar R, Underwood K, O'Connor AE, Loveland KL, Seehra JS, Matzuk MM: Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein. Mol Hum Reprod. 2007, 13: 675-683. 10.1093/molehr/gam055. Ehata S, Hanyu A, Fujime M, Katsuno Y, Fukunaga E, Goto K, Ishikawa Y, Nomura K, Yokoo H, Shimizu T, et al.: Ki2 a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci. 6894, 98 (1): 127-133. 10.1111/j.1349-7006.2006.00357.x. Ogino H, Yano S, Kakiuchi S, Muguruma H, Ikuta K, Hanibuchi M, Uehara H, Tsuchida K, Sugino H, Sone S: Follistatin suppresses the production of experimental multiple-organ metastasis by small cell lung cancer cells in natural killer cell-depleted SCID mice. Clin Cancer Res. 2008, 14: 660-667. 10.1158/1078-0432.CCR-07-1221. Hjelmeland MD, Hjelmeland AB, Sathornsumetee S, Reese ED, Herbstreith MH, Laping NJ, Friedman HS, Bigner DD, Wang XF, Rich JN: SB-43 a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther. 1542, 3: 737-745. Halder SK, Beauchamp RD, Datta PK: A specific inhibitor of TGF-beta receptor kinase, SB-43 as a potent antitumor agent for human cancers. Neoplasia. 1542, 7: 509-521. 10.1593/neo.04640. Futakuchi M, Nannuru KC, Varney ML, Sadanandam A, Nakao K, Asai K, Shirai T, Sato SY, Singh RK: Transforming growth factor-beta signaling at the tumor-bone interface promotes mammary tumor growth and osteoclast activation. Cancer Sci. 2009, 100: 71-81. 10.1111/j.1349-7006.2008.01012.x. Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, Mangadu R, Liu YW, Platten M, Herrlinger U, et al.: SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res. 2004, 64: 7954-7961. 10.1158/0008-5472.CAN-04-1013. Roberts VJ, Barth SL: Expression of messenger ribonucleic acids encoding the inhibin/activin system during mid- and late-gestation rat embryogenesis. Endocrinology. 1994, 134: 914-923. 10.1210/en.134.2.914. Trudeau VL, Theodosis DT, Poulain DA: Activin facilitates neuronal development in the rat amygdala. Neurosci Lett. 1997, 237: 33-36. 10.1016/S0304-3940(97)00796-9. Andreasson K, Worley PF: Induction of beta-A activin expression by synaptic activity and during neocortical development. Neuroscience. 1995, 69: 781-796. 10.1016/0306-4522(95)00245-E. Inokuchi K, Kato A, Hiraia K, Hishinuma F, Inoue M, Ozawa F: Increase in activin beta A mRNA in rat hippocampus during long-term potentiation. FEBS Lett. 1996, 382: 48-52. 10.1016/0014-5793(96)00135-4. Shoji-Kasai Y, Ageta H, Hasegawa Y, Tsuchida K, Sugino H, Inokuchi K: Activin increases the number of synaptic contacts and the length of dendritic spine necks by modulating spinal actin dynamics. J Cell Sci. 2007, 120: 3830-3837. 10.1242/jcs.012450. Lai M, Gluckman P, Dragunow M, Hughes PE: Focal brain injury increases activin betaA mRNA expression in hippocampal neurons. Neuroreport. 1997, 8: 2691-2694. 10.1097/00001756-199708180-00011. Foster JA, Puchowicz MJ, McIntyre DC, Herkenham M: Activin mRNA induced during amygdala kindling shows a spatiotemporal progression that tracks the spread of seizures. J Comp Neurol. 2004, 476: 91-102. 10.1002/cne.20197. Hughes PE, Alexi T, Williams CE, Clark RG, Gluckman PD: Administration of recombinant human Activin-A has powerful neurotrophic effects on select striatal phenotypes in the quinolinic acid lesion model of Huntington's disease. Neuroscience. 1999, 92: 197-209. 10.1016/S0306-4522(98)00724-6. Wu DD, Lai M, Hughes PE, Sirimanne E, Gluckman PD, Williams CE: Expression of the activin axis and neuronal rescue effects of recombinant activin A following hypoxic-ischemic brain injury in the infant rat. Brain Res. 1999, 835: 369-378. 10.1016/S0006-8993(99)01638-8. Tretter YP, Hertel M, Munz B, ten Bruggencate G, Werner S, Alzheimer C: Induction of activin A is essential for the neuroprotective action of basic fibroblast growth factor in vivo. Nat Med. 2000, 6: 812-815. 10.1038/77548. Muller MR, Zheng F, Werner S, Alzheimer C: Transgenic mice expressing dominant-negative activin receptor IB in forebrain neurons reveal novel functions of activin at glutamatergic synapses. J Biol Chem. 2006, 281: 29076-29084. 10.1074/jbc.M604959200. Ageta H, Murayama A, Migishima R, Kida S, Tsuchida K, Yokoyama M, Inokuchi K: Activin in the brain modulates anxiety-related behavior and adult neurogenesis. PLoS ONE. 2008, 3: e1869-10.1371/journal.pone.0001869. Zheng F, Adelsberger H, Muller MR, Fritschy JM, Werner S, Alzheimer C: Activin tunes GABAergic neurotransmission and modulates anxiety-like behavior. Mol Psychiatry. 2009, 14: 332-346. 10.1038/sj.mp.4002131. Dow AL, Russell DS, Duman RS: Regulation of activin mRNA and Smad2 phosphorylation by antidepressant treatment in the rat brain: effects in behavioral models. J Neurosci. 2005, 25: 4908-4916. 10.1523/JNEUROSCI.5155-04.2005. Asashima M, Michiue T, Kurisaki A: Elucidation of the role of activin in organogenesis using a multiple organ induction system with amphibian and mouse undifferentiated cells in vitro. Dev Growth Differ. 2008, 50 (Suppl 1): S35-45. Phillips BW, Hentze H, Rust WL, Chen QP, Chipperfield H, Tan EK, Abraham S, Sadasivam A, Soong PL, Wang ST, et al.: Directed differentiation of human embryonic stem cells into the pancreatic endocrine lineage. Stem Cells Dev. 2007, 16: 561-578. 10.1089/scd.2007.0029. Xiao L, Yuan X, Sharkis SJ: Activin A maintains self-renewal and regulates fibroblast growth factor, Wnt, and bone morphogenic protein pathways in human embryonic stem cells. Stem Cells. 2006, 24: 1476-1486. 10.1634/stemcells.2005-0299. Xu RH, Sampsell-Barron TL, Gu F, Root S, Peck RM, Pan G, Yu J, Antosiewicz-Bourget J, Tian S, Stewart R, Thomson JA: NANOG is a direct target of TGFbeta/activin-mediated SMAD signaling in human ESCs. Cell Stem Cell. 2008, 3: 196-206. 10.1016/j.stem.2008.07.001. Minetti GC, Colussi C, Adami R, Serra C, Mozzetta C, Parente V, Fortuni S, Straino S, Sampaolesi M, Di Padova M, et al.: Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat Med. 2006, 12: 1147-1150. 10.1038/nm1479. Pisconti A, Brunelli S, Di Padova M, De Palma C, Deponti D, Baesso S, Sartorelli V, Cossu G, Clementi E: Follistatin induction by nitric oxide through cyclic GMP: a tightly regulated signaling pathway that controls myoblast fusion. J Cell Biol. 2006, 172: 233-244. 10.1083/jcb.200507083. Zimmers TA, Davies MV, Koniaris LG, Haynes P, Esquela AF, Tomkinson KN, McPherron AC, Wolfman NM, Lee SJ: Induction of cachexia in mice by systemically administered myostatin. Science. 2002, 296: 1486-1488. 10.1126/science.1069525. Colussi C, Gaetano C, Capogrossi MC: AAV-dependent targeting of myostatin function: follistatin strikes back at muscular dystrophy. Gene Ther. 2008, 15: 1075-1076. 10.1038/gt.2008.95. Kinouchi N, Ohsawa Y, Ishimaru N, Ohuchi H, Sunada Y, Hayashi Y, Tanimoto Y, Moriyama K, Noji S: Atelocollagen-mediated local and systemic applications of myostatin-targeting siRNA increase skeletal muscle mass. Gene Ther. 2008, 15: 1126-1130. 10.1038/gt.2008.24.